Home > Healthcare > Medical Devices > Diagnostic Devices > glucometer market
Get a free sample of Glucometer Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Glucometer Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Government and organizational initiatives aimed at heightening awareness among the public regarding diabetics stimulate the growth of the market.
The continuous glucose monitors segment garnered USD 8.9 billion in 2023 and will grow significantly through 2032 due to their real-time monitoring capabilities, providing comprehensive insights into glycemic status and enabling prompt decision-making for diabetes management.
The global glucometer industry was valued at around USD 16.3 billion in 2023 and is estimated to reach over USD 46.8 billion by 2032, owing to the significant increase in the prevalence of diabetes in both developed and developing economies.
North America glucometer market accounted for USD 6.2 billion in 2023 and is predicted to witness substantial growth over 2024-2032, attributed to the region's relatively high prevalence of diabetes, increased awareness about diabetes management, and the availability of technologically advanced glucometers.
Abbott Laboratories, AgaMatrix, All Medicus Co., Ltd., Arkray, Inc., Ascensia Diabetes Care Holdings AG, B. Braun Melsungen AG, Bionime Corporation, DarioHealth Corporation, Dexcom, Inc., Essenlife Bioscience, Inc., F. Hoffmann-La Roche Ltd., LifeScan Inc., Medtronic plc, Nova Biomedical, Inc., and Sinocare Inc.